Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Micro-Tech (Nanjing) Co., Ltd. (688029.SS)
Nanjing, CN
Micro-Tech (Nanjing) Co., Ltd. is a key manufacturer and global supplier of non-vascular stents and disposable biopsy forceps. The company's primary markets span China, Europe, North America, and Oceania. Its extensive product portfolio includes specialized gastroenterology devices such as longwire and shortwire biliary stents, biopsy instruments, dilation and hemostasis products, EUS tools, nitinol stents, resection devices, retrieval systems, and related accessories. For pulmonology, offerings comprise airway stents, biopsy tools, dilation balloons, cytology brushes, retrieval devices, and additional accessories. Beyond its own product lines, Micro-Tech also provides original equipment manufacturing (OEM) and original design manufacturing (ODM) services to other medical device firms. Founded in 1999, the company is headquartered in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.49% | +1.88% | -3.66% | -0.75% | +3.50% | +0.43% | +21.67% | -10.09% | -59.35% | +3.76% | +3.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+15.8% ★ Q1'26: +22.1% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+3.4% Q1'26: -9.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+16.4% Q1'26: -0.1% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+21.7% ★ Q1'26: +21.4% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+19.9% ★ Q1'26: +17.2% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.3% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.30× ★ Q1'26: 0.04× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.31B
est: 1.28B (+2.5%)
|
1.33B
est: 1.35B (-1.4%)
|
1.95B
est: 1.91B (+1.8%)
|
1.98B
est: 1.98B (+0.0%)
|
2.41B
est: 2.60B (-7.2%)
|
2.76B
est: 2.76B (-0.2%)
|
3.19B
est: 3.23B (-1.1%)
|
3.72B
3.68B – 3.79B
+15.1% YoY
|
4.32B
4.11B – 4.70B
+16.2% YoY
|
5.01B
4.98B – 5.03B
+16.0% YoY
|
| EBITDA |
384.25M
est: 254.70M (+50.9%)
|
331.72M
est: 268.67M (+23.5%)
|
418.62M
est: 381.90M (+9.6%)
|
426.77M
est: 395.48M (+7.9%)
|
632.57M
est: 620.91M (+1.9%)
|
732.24M
est: 659.76M (+11.0%)
|
753.91M
est: 771.17M (-2.2%)
|
887.81M
879.02M – 906.84M
+15.1% YoY
|
1.03B
981.10M – 1.12B
+16.2% YoY
|
1.20B
1.19B – 1.20B
+16.0% YoY
|
| EBIT |
364.65M
est: 226.14M (+61.3%)
|
305.30M
est: 238.55M (+28.0%)
|
382.01M
est: 339.07M (+12.7%)
|
374.50M
est: 351.13M (+6.7%)
|
573.28M
est: 563.06M (+1.8%)
|
670.83M
est: 598.29M (+12.1%)
|
692.50M
est: 699.33M (-1.0%)
|
805.10M
797.13M – 822.35M
+15.1% YoY
|
935.40M
889.70M – 1.02B
+16.2% YoY
|
1.09B
1.08B – 1.09B
+16.0% YoY
|
| Net Income |
303.60M
est: 284.78M (+6.6%)
|
260.76M
est: 271.73M (-4.0%)
|
324.75M
est: 336.89M (-3.6%)
|
330.59M
est: 327.25M (+1.0%)
|
485.92M
est: 532.09M (-8.7%)
|
553.23M
est: 559.33M (-1.1%)
|
570.11M
est: 555.85M (+2.6%)
|
642.15M
601.95M – 664.92M
+15.5% YoY
|
793.05M
693.28M – 894.66M
+23.5% YoY
|
921.96M
844.14M – 948.06M
+16.3% YoY
|
| SGA |
453.42M
est: 473.83M (-4.3%)
|
493.56M
est: 499.82M (-1.3%)
|
732.23M
est: 710.45M (+3.1%)
|
738.24M
est: 735.72M (+0.3%)
|
894.41M
est: 849.04M (+5.3%)
|
1.01B
est: 902.17M (+11.8%)
|
472.72M
est: 1.05B (-55.2%)
|
1.21B
1.20B – 1.24B
+15.1% YoY
|
1.41B
1.34B – 1.54B
+16.2% YoY
|
1.64B
1.63B – 1.64B
+16.0% YoY
|
| EPS |
1.90
est: 1.52 (+25.1%)
|
1.40
est: 1.45 (-3.4%)
|
1.74
est: 1.80 (-3.1%)
|
1.77
est: 1.75 (+1.4%)
|
2.59
est: 2.84 (-8.8%)
|
2.95
est: 2.94 (+0.3%)
|
3.05
est: 3.10 (-1.5%)
|
3.39
3.22 – 3.56
+9.4% YoY
|
4.03
3.71 – 4.79
+18.8% YoY
|
4.79
4.52 – 5.07
+18.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 4/5 | 1/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.85% | 601.3K | 0.95% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 28.3K | 0.44% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 209.8K | 0.39% |
| 4 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 184.0K | 0.06% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 79.3K | 0.17% |
| 6 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 79.3K | 0.17% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 120.0K | 0.29% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 38.5K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.1K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.90M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Zhang | Senior Vice President & Director | — | male |
| Changqing Li | Executive President & Director | — | male |
| Chenwei Rui | Senior Vice President, Chief Financial Officer & Chief Accountant | — | male |
| Daniel Kuhn | Senior Vice President | — | male |
| Derong Leng | President & Director | — | male |
| Feng Zhang | Senior Vice President | — | male |
| Gong Xingliang | Vice President & Secretary of the Board | — | male |
| Jian Yu Wei | Senior Chief Engineer | — | male |
| Jiefeng Xi | Chief Scientist and Senior Director of R&D | — | male |
| Ning Li | Director of Quality & Regulatory Affairs | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688029.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
